Namwiwat Medical (NAM) Fair Value & Analysis
Healthcare · TH · Market cap 2.4B THB (≈ $73.2M)
What is Namwiwat Medical really worth?
Below-average quality, currently priced close to our fair value of 3.19 THB.
Strengths
Risks
For context
Fair value as of: Aug 19, 2026
From 15 valuation models · updated 16 days ago
Share price −3.5% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
34‑month range 3.28 THB – 6.68 THB · fair‑value band 2.39 THB – 3.99 THB · the 3.28 THB price screens above the 3.19 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Namwiwat Medical (NAM) currently trades at 3.28 THB, while our model-based Fair Value estimate is 3.19 THB, implying the stock looks roughly 2.8% fairly valued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of 5.35 THB per share, and 6 of the 15 models we run sit above the 3.28 THB price. Bear case: the Asset-Based group reads lowest at 1.91 THB, and 9 of the 15 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Namwiwat Medical generated revenue of 1.7B THB at a net margin of 4.0%. Revenue declined 29.9% year over year. It earns a return on equity of 3.4%. Net debt stands at 190M THB. Fundamentals as of Aug 19, 2026
Our scenario range runs from 2.39 THB (bear case) to 3.99 THB (bull case); at 3.28 THB, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 23% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −3%, NAM screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 15 models by family
Widest divergence: DCF Models (5.35 THB) versus Asset-Based (1.91 THB). Highest evidence: Residual Income (73).
Notify me when NAM reaches fair value
Put NAM on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Namwiwat Medical Corporation Public Company Limited manufactures and distributes medical equipment in Thailand. The company offers steam and low temperature sterilizers, instrument washer disinfectors, ultrasonic cleaning systems, and drying cabinets, as well as waste sterilizers.
Full company description
Namwiwat Medical Corporation Public Company Limited manufactures and distributes medical equipment in Thailand. The company offers steam and low temperature sterilizers, instrument washer disinfectors, ultrasonic cleaning systems, and drying cabinets, as well as waste sterilizers. It also provides NAMTrack, a central sterile supply department software management product, as well as Air Track. In addition, the company offers air and surface disinfection equipment and air purifiers. Further, it provides medical supplies, disinfection services, medical equipment maintenance services, infectious waste services, and other medical services. The company was founded in 1970 and is based in Samut Prakan, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Namwiwat Medical reported revenue of 1.9B THB in FY2026 versus 992M THB in FY2022, a compound +17.2%/yr. Reported net income was 102M THB in FY2026, compounding −12.7%/yr from FY2022.
Watch NAM: get an alert when its fair value changes →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $89.78 | $41.02 | −54% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
Compare Namwiwat Medical with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Namwiwat Medical (NAM) overvalued or undervalued?
What is the fair value of NAM?
What is the quality score of NAM?
What is the revenue of Namwiwat Medical (NAM)?
What is the net profit margin of NAM?
Does Namwiwat Medical pay a dividend?
Watch Namwiwat Medical in the live analysis
One click puts Namwiwat Medical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.